FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

The U.S. Food and Drug Administration (FDA) has proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, asserting there is no clinical need for outsourcing facilities to compound these drugs from bulk substances. This action, announced on April 30, 2026, aims to protect patients and uphold the integrity of the drug approval process, as FDA-approved versions are available. The agency is inviting public comments on this proposal until June 29, 2026, before making a final determination, emphasizing a transparent, science-based approach to regulatory decisions.

• The FDA's proposal targets semaglutide, tirzepatide, and liraglutide for exclusion from the 503B bulks list, which identifies substances outsourcing facilities can use for compounding. The agency's primary rationale is the absence of a clear clinical need for compounding these drugs from bulk substances, especially given the availability of FDA-approved drug products. This move reinforces the principle that compounding from bulk substances by outsourcing facilities is generally restricted unless a specific clinical need or drug shortage is identified.
• This regulatory action is grounded in section 503B of the Federal Food, Drug, and Cosmetic Act, which outlines the conditions for compounding by outsourcing facilities. FDA Commissioner Marty Makary underscored the agency's commitment to patient protection and preserving the integrity of the drug approval pathway. The FDA's determination of "no clinical need" was based on a thorough review of nominations, prioritizing patient safety and medical necessity as mandated by law.
• To ensure transparency and gather comprehensive input, the FDA has initiated a public comment period for this proposal. Interested parties are encouraged to submit their electronic comments through the official docket by June 29, 2026. The agency has committed to carefully considering all submitted feedback before issuing a final determination on the inclusion or exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list, highlighting a science-based approach to regulatory policy.

Safety and Tolerability of Approved GLP-1 Agonists

Published safety data demonstrates that semaglutide, tirzepatide, and liraglutide exhibit distinct adverse event profiles while sharing common class-related effects. Analysis of large-scale pharmacovigilance data and clinical trials reveals differential risk patterns across gastrointestinal, psychiatric, and systemic adverse events. Overall, these agents maintain favorable benefit-risk profiles, though specific monitoring considerations apply to each compound.

• Gastrointestinal adverse events represent the most common tolerability issue across all three agents, with liraglutide showing the highest rates (up to 40%), followed by semaglutide weekly (22% nausea, 11% diarrhea, 7% vomiting), and tirzepatide demonstrating dose-dependent effects (17-22% nausea, 13-16% diarrhea)

• Psychiatric adverse events show significant differential risk, with semaglutide demonstrating the strongest disproportionality signals for anxiety (PRR 1.34), depression (PRR 1.83), and suicidal ideation (PRR 3.44), while liraglutide presents a comparatively lower psychiatric risk profile

• Vestibular disorders occur more frequently with both semaglutide and tirzepatide compared to controls, with semaglutide showing higher cumulative incidence (0.41% at 3 years) and greater risk versus tirzepatide (RR 1.53-2.04)

• Injection-site reactions and inappropriate use are markedly elevated with tirzepatide (PRR 7.98 for injection-site reactions, PRR 5.98 for inappropriate administration) compared to semaglutide and liraglutide

• Treatment discontinuation rates are highest with maximum tolerated doses of semaglutide (OR 7.36) and tirzepatide (OR 5.56), primarily due to gastrointestinal intolerance, while tirzepatide shows the lowest overall pharmacovigilance association strength

• Cardiovascular benefits with established safety profiles are demonstrated for semaglutide (RR 0.83 for MACE) and liraglutide (RR 0.87 for MACE), though semaglutide carries increased diabetic retinopathy complication risk (HR 1.76) in vulnerable populations

Beyond Approved Uses: GLP-1 Agonists in Clinical Trials

GLP-1 receptor agonists are being investigated across multiple therapeutic areas beyond their approved metabolic indications, with particular focus on cardiovascular, neurological, and hepatic conditions. The clinical trial landscape demonstrates diverse intervention models ranging from parallel-arm designs to placebo-controlled studies, with varying treatment durations and patient populations.

The Evolving Landscape of GLP-1 Receptor Agonists

Several emerging GLP-1 receptor agonists are advancing through clinical development for obesity and diabetes management, expanding the therapeutic landscape beyond established agents. While specific trial design details are limited in the available literature, these investigational compounds demonstrate promising efficacy profiles for weight reduction and metabolic control.

Upholding Drug Integrity: The Future of GLP-1 RA Access

The FDA's recent proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list marks a pivotal moment for the pharmaceutical landscape, particularly within the burgeoning market of GLP-1 receptor agonists. This move, grounded in the availability of FDA-approved versions, aims to safeguard patients and uphold the rigorous standards of drug development and approval. For manufacturers of these highly effective therapies, this decision solidifies their market position by eliminating a significant source of compounded alternatives. These branded products, extensively studied and approved for indications ranging from type 2 diabetes and obesity to metabolic dysfunction-associated steatohepatitis, have demonstrated robust efficacy in glycemic control, weight reduction, and cardiovascular risk improvement.

However, the implications extend beyond market protection. The immense demand for GLP-1 RAs, partly fueled by off-label use for weight loss, has already strained supply chains and created access challenges for patients with FDA-approved diagnoses. Removing compounded options, which some patients may have sought due to lower costs or perceived easier access, could exacerbate these issues. Studies indicate significant financial barriers and insurance coverage disparities exist, particularly for semaglutide-eligible populations. This regulatory tightening, while ensuring product quality and safety, risks pushing some patients towards entirely unregulated or illicit sources if legitimate access remains difficult or unaffordable.

Looking ahead, this action underscores the critical need for manufacturers to not only scale up production to meet demand but also to engage proactively with payers and policymakers to improve insurance coverage and affordability. Furthermore, the emphasis on regulatory integrity highlights the ongoing importance of robust pharmacovigilance. While GLP-1 RAs offer transformative benefits, clinicians must remain vigilant regarding potential adverse events, including gastrointestinal issues, acute kidney injury, and even rare ocular signals, ensuring patient education is paramount. The FDA's transparent, science-based approach invites public comment, signaling an opportunity for stakeholders to contribute to a balanced solution that prioritizes both patient safety and equitable access to these life-changing medications.